BiotechTube

DS-3201b

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Impairment

Conditions

Hepatic Impairment

Trial Timeline

Nov 21, 2019 → Feb 23, 2021

NCT ID
NCT04276662

About DS-3201b

DS-3201b is a phase 1 stage product being developed by Daiichi Sankyo for Hepatic Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT04276662. Target conditions include Hepatic Impairment.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT04276662Phase 1Completed
NCT03110354Phase 1Terminated

Competing Products

20 competing products in Hepatic Impairment

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
25
GB1211 + PlaceboComac MedicalPhase 1/2
33
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
28
OlomorasibEli LillyPhase 1
33
SimufilamCassava SciencesPhase 1
25
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
QuizartinibDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
PexidartinibDaiichi SankyoPhase 1
33
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
33
BocidelparAstellas PharmaPhase 1
33
fezolinetantAstellas PharmaPhase 1
33
enzalutamideAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP2215Astellas PharmaPhase 1
33
BPN14770ShionogiPhase 1
33
S-217622ShionogiPhase 1
33
LemborexantEisaiPhase 1
33
LenvatinibEisaiPhase 1
33

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85